Johnson and colleagues said the disparity between eligibility and donor availability has long been particularly pronounced among Black patients. That was the lowest percentage of any racial or ethnic group studied.2 Johnson and colleagues said such disparities were believed to be tied to a lack of suitable matched donors among Black patients. The authors pulled data on patients diagnosed with AML between the years 2004 and 2019, finding a total of 85,787 patients. The AACs in allo-HCT rates were –0.53% (95% CI, –0.72% to –0.35%) for people on Medicaid and –0.94% (95% CI, –1.03% to –0.86%) for those with Medicare, compared to people with private insurance. In short, the data indicate “a lower rate of increase in allo-HCT utilization and widening disparities” in allo-HCT access.